Tricida is an innovative pre-clinical stage biopharmaceutical company focused on the discovery and development of first-in-class therapeutics for metabolic, renal and cardiovascular disease. Tricida’s lead program is TRC101, a novel treatment for complications of chronic kidney disease (CKD). Tricida is led by an experienced and accomplished management team that has worked together for 10 plus years and has raised >$250 M in venture capital from world-class investors over three companies. This team brings their proven leadership and expertise to address the specific disease profile of chronic kidney disease and related complications. The National Health and Nutrition Examination Surveys (NHANES, 1988-1994 and 1999-2004) estimate that over 26 million adults in the United States have chronic kidney disease, with substantial morbidity and mortality associated with the progressive loss of kidney function. The scientists and clinicians at Tricida aim to provide physicians with new drug treatment options to help control the disease and reduce the number of CKD patients requiring dialysis. Tricida’s shared culture of teamwork, comradery and empowerment is evident in the dedication and focus our employees demonstrate, with a commitment to the ultimate goal of improving and prolonging the lives of people living with CKD. If you share our passion for breaking new ground in the discovery and development of first-in-class therapeutics, and are dedicated to building a company centered on cutting-edge science that delivers new innovations to patients, then we would like to speak with you. We seek talented and high-achieving professionals to join us as we work towards bringing critically needed new therapies to patients.
Show more
Type
Private
HQ
South San Francisco, US
Founded
2013
Size (employees)
46 (est)-2%
Tricida was founded in 2013 and is headquartered in South San Francisco, US
Report incorrect company information

Key People/Management at Tricida

Gerrit Klaerner PhD

Gerrit Klaerner PhD

Chief Executive Officer & President
Jeroen van Beek PhD

Jeroen van Beek PhD

Chief Commercial Officer & Senior Vice President
Jerry M. Buysse PhD

Jerry M. Buysse PhD

Chief Scientific Officer & Senior Vice President
Edward J. Hejlek JD

Edward J. Hejlek JD

General Counsel & Senior Vice President
Claire Lockey

Claire Lockey

Chief Development Officer & Senior Vice President
Geoffrey Parker

Geoffrey Parker

Chief Financial Officer & Senior Vice President
Show more

Tricida Office Locations

Tricida has an office in South San Francisco
South San Francisco, US (HQ)
201 7000 Shoreline Ct
Show all (1)
Report incorrect company information

Tricida Financials and Metrics

Summary Metrics

Founding Date

2013

Total Funding

$157 m

Latest funding size

$57.50 m

Time since last funding

6 months ago

Investors

Tricida's latest funding round in November 2017 was reported to be $57.5 m. In total, Tricida has raised $157 m
Show all financial metrics
Report incorrect company information

Tricida News and Updates

Tricida to secure $100 mln debt financing

Hercules Capital has agreed to provide a $100 million venture debt facility to South San Francisco-based Tricida Inc, a pharmaceutical company focused on treating metabolic acidosis. Armentum Partners provided financial advice to Tricida on the transaction while Sidley Austin LLP was legal adviser.

Tricida fetches $57.5 mln Series D

South San Francisco, California-based Tricida, Inc, a developer of oral drug therapies, has raised $57.5 million in Series D financing. The investors were Wellington Management Company LLP, Venrock Healthcare Capital Partners, Cormorant Asset Management, OrbiMed, Longitude Capital, Sibling Capital V…
Report incorrect company information